**Appendix 2- Subgroup analyses – European guideline targets**

Appendix 2 Table. Achievement of all threea European treatment targets simultaneously by subgroup at 12 months

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Subgroup  | Polypill-based care  | Usual care  | RRb (95% CI) | p hetb |
| n/N (crude %) | Estimatedb % (95% CI) | n/N (crude %) | Estimatedb % (95% CI) |  |  |
| Age (years) | </=62 | 167/ 691 (24%) | 24% (21-28%) | 117/ 663 (18%) | 18% (15-21%) | 1.37 (1.11-1.69) | 0.350 |
| >62 | 164/ 686 (24%) | 24% (21-27%) | 135/ 673 (20%) | 20% (17-23%) | 1.19 (0.97-1.46) |
| Sex | Female | 66/ 330 (20%) | 20% (16-25%) | 49/ 311 (16%) | 16% (12-20%) | 1.27 (0.91-1.78) | 0.971 |
| Male | 265/ 1047 (25%) | 25% (23-28%) | 203/ 1025 (20%) | 20% (18-22%) | 1.28 (1.09-1.50) |
| Baseline treatment modalities | 0-1 | 42/ 121 (35%) | 34% (27-44%) | 14/ 124 (11%) | 11% (7-18%) | 3.07 (1.77-5.33) | 0.001 |
| 2 | 54/ 201 (27%) | 27% (21-34%) | 30/ 181 (17%) | 17% (12-23%) | 1.62 (1.09-2.42) |
| 3 | 235/1055 (22%) | 22% (20-25%) | 208/1031 (20%) | 20% (18-23%) | 1.10 (0.94-1.30) |
| Baseline use of all indicatedc medications  | No | 172/ 635 (27%) | 27% (24-31%) | 95/ 581 (16%) | 16% (14-20%) | 1.66 (1.32-2.07) | 0.002 |
| Yes | 159/ 724 (21%) | 21% (19-25%) | 157/ 755 (21%) | 21% (18-24%) | 1.03 (0.85-1.25) |
| CVD | No | 112/ 322 (35%) | 35% (28-43%) | 70/ 298 (24%) | 23% (18-30%) | 1.48 (1.15-1.91) | 0.151 |
| Yes | 219/1055 (21%) | 18% (15-23%) | 182/1038 (18%) | 16% (12-19%) | 1.18 (0.99-1.41) |

CI=confidence interval, CVD=cardiovascular disease, het=heterogeneity (between subgroups), RR=risk ratio

aAntiplatelet target only applicable to people with established cardiovascular disease

bEstimated proportions, RR and p het were obtained from a log-binomial regression model as described in the methods section of the main paper

cStatin, antiplatelet and >2 BP-lowering medications; all were indicated according to the participant’s physician on trial entry